Savara Inc. $SVRA Shares Bought by Bain Capital Life Sciences Investors LLC

Key Points

• Bain Capital Life Sciences Investors LLC increased its stake in Savara Inc. by 20.8%, owning approximately 17.6 million shares, making it the 6th largest position in their portfolio.
• Savara reported a net loss of $0.14 per share in its latest earnings call, missing the consensus estimate by $0.02, with analysts predicting a -0.45 EPS for the current year.
• Insider trading activity included Director Richard J. Hawkins purchasing 48,225 shares at $2.04 per share, increasing his ownership by 71.72%.

Bain Capital Life Sciences Investors LLC lifted its position in Savara Inc. (NASDAQ:SVRA - Free Report) by 20.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,600,621 shares of the company's stock after acquiring an additional 3,035,164 shares during the quarter. Savara accounts for approximately 7.2% of Bain Capital Life Sciences Investors LLC's holdings, making the stock its 6th largest position. Bain Capital Life Sciences Investors LLC owned 10.19% of Savara worth $48,754,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in SVRA. Frazier Life Sciences Management L.P. grew its position in shares of Savara by 32.4% in the 1st quarter. Frazier Life Sciences Management L.P. now owns 11,462,301 shares of the company's stock worth $31,751,000 after acquiring an additional 2,801,922 shares in the last quarter. Vestal Point Capital LP grew its position in shares of Savara by 33.2% in the 4th quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company's stock worth $33,079,000 after acquiring an additional 2,685,000 shares in the last quarter. Farallon Capital Management LLC grew its position in shares of Savara by 49.9% in the 4th quarter. Farallon Capital Management LLC now owns 6,835,000 shares of the company's stock worth $20,983,000 after acquiring an additional 2,275,000 shares in the last quarter. Deerfield Management Company L.P. Series C grew its position in shares of Savara by 23.2% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 7,964,000 shares of the company's stock worth $24,449,000 after acquiring an additional 1,498,223 shares in the last quarter. Finally, Emerald Advisers LLC grew its position in shares of Savara by 32.5% in the 1st quarter. Emerald Advisers LLC now owns 3,090,213 shares of the company's stock worth $8,560,000 after acquiring an additional 757,533 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

Savara Stock Up 0.9%

Shares of Savara stock opened at $3.31 on Wednesday. The business's fifty day moving average price is $2.63 and its two-hundred day moving average price is $2.69. The company has a debt-to-equity ratio of 0.25, a current ratio of 11.08 and a quick ratio of 11.08. The company has a market capitalization of $572.10 million, a P/E ratio of -6.62 and a beta of 0.56. Savara Inc. has a 1-year low of $1.89 and a 1-year high of $4.70.

Savara (NASDAQ:SVRA - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). As a group, research analysts forecast that Savara Inc. will post -0.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on SVRA. Evercore ISI decreased their target price on Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a research report on Wednesday, May 28th. Oppenheimer raised their price target on Savara from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday, August 15th. HC Wainwright raised Savara from a "neutral" rating to a "buy" rating and raised their price target for the stock from $2.00 to $5.00 in a report on Friday, August 15th. Guggenheim reissued a "buy" rating and issued a $8.00 price target (down previously from $9.00) on shares of Savara in a report on Wednesday, May 28th. Finally, Wells Fargo & Company cut their price target on Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Wednesday, May 28th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $6.17.

Insiders Place Their Bets

In other Savara news, Director Richard J. Hawkins bought 48,225 shares of the business's stock in a transaction on Friday, June 20th. The shares were purchased at an average price of $2.04 per share, with a total value of $98,379.00. Following the purchase, the director directly owned 115,466 shares of the company's stock, valued at approximately $235,550.64. The trade was a 71.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 5.13% of the stock is owned by insiders.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.